Investor Overview

Corporate Profile

Investor Highlights

Corporate Profile

Read Now

Corporate Profile

Investor Presentation

Read Now

highlightbg1

Our Pipeline

Learn More
highlightbg2
  • Price
  • Change

  • Copyright West LLC.
    Minimum 15 minutes delayed.
Recent Releases

Recent Releases

March 25, 2020

BeiGene Announces Supply Update for ABRAXANE® in China

March 2, 2020

BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results

February 27, 2020

MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors

Key Metrics

Key Metrics

  • 3,500+

    Employees

  • 1,100+

    Clinical team

  • 4

    Continents

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept